Pembrolizumab for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC): Efficacy and safety results from the phase II KEYNOTE-629 study

被引：0
|
作者：
Grob, J. J. [1 ]
Gonzalez Mendoza, R. [2 ]
Basset-Seguin, N. [3 ]
Vornicova, O. [4 ]
Schachter, J. [5 ]
Joshi, A. [6 ]
Meyer, N. [7 ]
Grange, F. [8 ]
Piulats, J. M. [9 ]
Bauman, J. [10 ]
Zhang, P. [11 ]
Gumuscu, B. [11 ]
Swaby, R. F. [11 ]
Hughes, B. G. M. [12 ]
机构：
[1] AIX Marseille Univ, Dermatol, Marseille, France
[2] Ctr Estatal Cancerol Chihuahua, Surg Oncol, Chihuahua, Mexico
[3] Hop St Louis, Dermatol, Paris, France
[4] Rambam Hlth Care Campus, Oncol, Haifa, Israel
[5] Sheba Med Ctr Tel Hashomer, Div Oncol, Ramat Gan, Israel
[6] Townsville Canc Ctr, Med Oncol, Townsville, Qld, Australia
[7] IUCT Oncopole, Med Oncol, Toulouse, France
[8] Hop Robert Debre, CHU Reims, Dermatol Oncol, Reims, France
[9] Hosp Duran & Reinals ICO Hospitalet, Genitourinary Melanoma & Sarcoma Unit, Med Oncol, Barcelona, Spain
[10] Fox Chase Canc Ctr, Hematol Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[11] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[12] Univ Queensland, Royal Brisbane & Womens Hosp, Oncol, Brisbane, Qld, Australia
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA72
引用
收藏
页码：908 / 908
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study
    Shapira-Frommer, Ronnie
    Mileshkin, Linda
    Manzyuk, Ludmila
    Penel, Nicolas
    Burge, Matthew
    Piha-Paul, Sarina A.
    Girda, Eugenia
    Martin, Jose A. Lopez
    Van Dongen, Marloes G. J.
    Italiano, Antoine
    Xu, Lei
    Jin, Fan
    Norwood, Kevin
    Ott, Patrick A.
    GYNECOLOGIC ONCOLOGY, 2022, 166 (02) : 211 - 218
  • [22] The KEYNOTE-630 Trial: A Phase 3 Study of Adjuvant Pembrolizumab in High -Risk Locally Advanced (LA) Cutaneous Squamous Cell Carcinoma (cSCC)
    Schenker, M.
    Klochikhin, M.
    Kirtbaya, D.
    Mother, L.
    Gschnell, M.
    Robert, C.
    Meyer, N.
    Flatz, L.
    Dalle, S.
    Beylot-Barry, M.
    Eigentler, T.
    Silverman, R. Kloss
    Gumuscu, B.
    Yuan, J.
    Bratland, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E81 - E82
  • [23] Pembrolizumab for vulvar squamous cell carcinoma: results from the phase 2 KEYNOTE-158 study
    Frommer, Ronnie Shapira
    Mileshkin, Linda
    Manzyuk, Ludmila
    Penel, Nicolas
    Burge, Matthew
    Piha-Paul, Sarina
    Girda, Eugenia
    Martin, Jose Lopez
    van Dongen, Marloes
    Italiano, Antoine
    Xu, Lei
    Jin, Fan
    Norwood, Kevin
    Ott, Patrick
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S44 - S44
  • [24] Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
    Marabelle, Aurelien
    Cassier, Philippe Alexandre
    Fakih, Marwan
    Guren, Tormod Kyrre
    Italiano, Antoine
    Kao, Steven Chuan-Hao
    Nielsen, Dorte
    Ascierto, Paolo Antonio
    Bariani, Giovanni M.
    Santoro, Armando
    Shah, Manisha H.
    Asselah, Jamil
    El-Khoueiry, Anthony B.
    Spencer, Kristen Renee
    Takahashi, Shunji
    Chatterjee, Arkendu
    Jin, Fan
    Norwood, Kevin
    Delord, Jean-Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [25] Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus The Phase 2 KEYNOTE-180 Study
    Shah, Manish A.
    Kojima, Takashi
    Hochhauser, Daniel
    Enzinger, Peter
    Raimbourg, Judith
    Hollebecque, Antoine
    Lordick, Florian
    Kim, Sung-Bae
    Tajika, Masahiro
    Kim, Heung Tae
    Lockhart, A. Craig
    Arkenau, Hendrik-Tobias
    El-Hajbi, Farid
    Gupta, Mukul
    Pfeiffer, Per
    Liu, Qi
    Lunceford, Jared
    Kang, S. Peter
    Bhagia, Pooja
    Kato, Ken
    JAMA ONCOLOGY, 2019, 5 (04) : 546 - 550
  • [26] KEYNOTE-630: Phase 3 study of pembrolizumab as adjuvant treatment in high-risk locally advanced (LA) cutaneous squamous cell carcinoma (cSCC)
    Lee, Jenny
    Dzienis, Marcin
    Schmults, Chrysalyne
    Schneker, Michael
    Bratland, Ase
    Klochikhin, Mikhail
    Gifoni, Markus
    Kirtbaya, Dmitry
    Rivera-Diaz, Julian
    Chipman, Mitchell
    Geiger, Jessica L.
    Chang, Anne L. S.
    Daniels, Gregory A.
    Cohen, Ezra E. W.
    Yao, Lili
    Gumuscu, Burak
    Yuan, Jianda
    Guminski, Alexander
    Bowers, Elani
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 234 - 235
  • [27] Pembrolizumab as first-line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC): Phase 2 results from CARSKIN.
    Maubec, Eve
    Boubaya, Marouane
    Petrow, Peter
    Basset-Seguin, Nicole
    Grob, Jean Jacques
    Dreno, Brigitte
    Beylot-Barry, Marie
    Scheer-Senyarich, Isabelle
    Helfen, Sabine
    Leccia, Marie Therese
    Stefan, Andreea Raluca
    Saiag, Philippe
    De Quatrebarbes, Julie
    Meyer, Nicolas
    Deschamps, Lydia
    Alloux, Celine
    Lopez, Isabelle
    Cherbal, Soufian
    Tibi, Annick
    Levy, Vincent
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] Development of a metastatic risk index for cutaneous squamous cell carcinoma (cSCC): A pilot study
    Chu, Melinda
    Armbrecht, Eric
    Fosko, Scott
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB97 - AB97
  • [29] Efficacy and safety of CetuGEX in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-NSCC): Results from the randomized phase II RESGEX study.
    Keilholz, Ulrich
    Kawecki, Andrzej
    Dietz, Andreas
    Zurawski, Bogdan
    Schenker, Michael
    Kukielka-Budny, Bozena
    Schafhausen, Philippe
    Mihailov, Anca C.
    Ochenduszko, Sebastian
    Imarisio, Ilaria
    Mihutiu, Simona
    Oprean, Cristina-Marinela
    Folprecht, Gunnar
    Turcu, Alina
    Rottey, Sylvie
    Debourdeau, Philippe
    Lavernia, Javier
    Dietrich, Bruno
    Zurlo, Alfredo
    Fayette, Jerome
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [30] Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040
    Harrington, Kevin J.
    Soulieres, Denis
    Le Tourneau, Christophe
    Dinis, Jose
    Licitra, Lisa F.
    Ahn, Myung-Ju
    Soria, Ainara
    Machiels, Jean-Pascal H.
    Mach, Nicolas
    Mehra, Ranee
    Burtness, Barbara
    Ellison, Misoo C.
    Cheng, Jonathan D.
    Chirovsky, Diana Romana
    Swaby, Ramona F.
    Cohen, Ezra E. W.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (02): : 171 - 181
12345